natgillin/translations-raw huggingface dataset:
The genetically modified murine animal of claim 1, wherein the murine animal expresses a humanized IL-6Ra wherein the endogenous murine IL-6Ra gene has been replaced with a human sequence comprising a sequence that encodes an ectodomain of a human IL-6Ra. 
Genetički modificirani miš prema zahtjevu 1, naznačen time da miš eksprimira humanizirani 1I-6Ra. pri čemu je endogeni mišji IL-6Ra gen zamijenjen ljudskom sekvencom koja sadrži sekvencu koja kodira ektodomenu za ljudski IL-6Ra.
These may include 5, 10, 20, 30 or 40 mg patches. 
Ovi mogu uključivati flastere s 5, 10, 20, 30 ili 40 mg.
The method of any one of claims 1-3, wherein the immunobinder is a scFv antibody, a full-length immunoglobulin, a Fab fragment, a Dab or a Nanobody. 
Metoda iz bilo kojeg od zahtjeva 1-3, naznačena time da je vezno antitijelo scFv antitijelo, imunoglobulin pune dužine, Fab fragment, Dab ili nanotijelo.
150 mg/mL, based on the total volume of the composition. The pharmaceutical composition according to Embodiment 1, wherein the S-ketamine hydrochloride is present in a concentration in the range of 126 mg / mL to 162 mg/mL, based on the total volume of the composition. 
150 mg/mL, na temelju ukupnog volumena sastava; ili pri čemu S-ketamin hidroklorid se nalazi u koncentraciji u opsegu od 126 mg / mL do 162 mg/mL, na temelju ukupnog volumena sastava.
As a consequence of its exceptional water binding ability even relatively dilute aqueous solutions of HA show high viscosity. 
Kao posljedica njegove izuzetne sposobnosti vezanja vode čak i relativno razrijeđenih vodenih otopina HA pokazuje visoki viskozitet.
A solid system in the form of a tablet or capsule for oral administration comprising a polymeric matrix comprising an ionic polymer which is hyaluronic acid in the form of free acid with a weighted-average molecular weight ranging from 100 to 100,000 Daltons (Da) measured with SEC-MALLS technique, a non-ionic polymer which jellifies in contact with a liquid, for use in modulating the release of one or more active ingredients from the solid system. 
Čvrsti sustav u obliku tablete ili kapsule za oralnu primjenu koji sadrži polimerni matriks koji sadrži ionski polimer koji je hijaluronska kiselina u obliku slobodne kiseline sa ponderiranom prosječnom molekulskom masom u opsegu od 100 do 100,000 Daltona (Da) izmjerenom s SEC-MALLS tehnikom, neionski polimer koji se pretvara u želatinoznu masu u kontaktu s tekućinom, za upotrebu u modulaciji oslobađanja jednog ili više aktivnih sastojaka iz čvrstog sustava.
As can be seen in Fig. 14, the rotational axis 63' of the rotary machining tool 63" extends essentially perpendicular to the surface of the piece of wood 10 to be processed. 
Kao što se može vidjeti na slici 14, os rotacije 63' rotirajućeg alatnog stroja 63" pruža se uglavnom okomito na površinu komada od drva 10 koji se treba obraditi.
Process according to claim 1 wherein the polyethylene composition satisfies the relationship: wt% PCR ≤ 74 - (14.4 x HL275A), wherein wt% PCR is the proportion in weight percent of the high density polyethylene post consumer resin in the composition relative to the total weight of the composition and HL275A is the HL275 of fraction A of the virgin Ziegler-Natta catalyzed polyethylene resin as determined according to ISO 1133, condition G, at 190°C and under a load of 21.6 kg except that a die of 2.75 mm broad was used. 
težinu sastava. Postupak prema zahtjevu 1 naznačeno time da polietilenski sastav zadovoljava odnos: 0% PCR<74 - (14.4 x HL.275A), naznačeno time da 0% PCR je razmjer težinskog udjela recikliranog polietilena visoke gustoće u sastavu u odnosu na ukupnu težinu sastava, te HL275A je HL275 frakcije A neobrađene Ziegler-Natta katalizirane polietilenske smole utvđrene prema ISO 1133, uvjet G, na 190"C 1 pod opterećenjem od 21.6kg osim što je korišten kalup širine 2.75mm.
The mixture had a dough-like consistency and was fed into an extruder. 
Smjesa je imala konzistenciju testa i šaržirana je u istiskivao.
The chemically modified glycosaminoglycan according to claim 1, wherein the chemically modified glycosaminoglycan is heparin. A method of preparing a chemically modified glycosaminoglycan selected from the group consisting of heparin and heparan sulfate which chemically modified glycosaminoglycan has an antifactor IIa activity and an antifactor Xa activity, with the antifactor IIa activity being less than 10 IU/mg and the antifactor Xa activity being less than 10 IU/mg, the chemically modified glycosaminoglycan having a weight average molecular weight (Mw) from about 4.6 to about 6.9 kDa, the method comprising the sequential steps of: 
5. < Kemijski modificirani glikozaminoglikan prema bilo kojem od zahtjeva 1-4, naznačen time da glikozaminoglikan koji je modificiran je heparin. 6. - Postupak dobivanja kemijski modificiranog sulfatiranog glikozaminoglikana koji se bira iz skupine koja se sastoji od heparina i heparan sulfata uz aktivnost antifaktora Ila koja je manja od 10 IU/mg, aktivnost antifaktora Xa koja je manja od 10 TU/mg i srednjom molekularnom masom (Mw) od 4,6 (+10%) do 6,9 (+10%) kDa, koji sadrži uzastopne korake:
A composition for use according to claim 9 wherein the patient has a rate of urine production during sleep that is greater than the patient's overall average daily rate of urine production; and/or wherein the patient is over 65 years of age with a serum sodium level of at least 135 after administration. 
Pripravak za uporabu prema zahtjevu 11, naznačen time da pacijent ima stopu proizvodnje urina tijekom spavanja veću od prosječne stope cjelodnevne proizvodnje urina pacijenta.
As stated in its US prescribing information, PROLEUKIN™ exists as biologically active, non-covalently bound microaggregates with an average size of 27 recombinant IL-2 molecules. 
Kako je navedeno u njegovoj informaciji za propisivanje u Sjedinjenim državama, PROLEUKINTM postoji kao biološki aktivni, nekovalentno vezani mikroagregati prosječne veličine od 27 rekombinantnih IL-2 molekula.
The formulation according to claim 14 which is capable of delivering 6 µg formoterol fumarate dihydrate and 100 µg beclometasone dipropionate per actuation. 
Formulacija prema patentnom zahtjevu 12 koja je sposobna isporučiti 6 µg formoterol-fumarat dihidrata i 100 µg beklometazon-dipropionata po pokretanju.
In certain embodiments, the pharmaceutical compositions described herein include a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof. 
Re S ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, tautomer, stereoizomer ili izotopno označen derivat, pri čemu je: prsten A" izabran od svaki od R', R* 1 R'" neovisno je izabran od vodika i metila;
About 00.1-3 % dehydrated alcohol. 
0,01-3%, težinski, dehidratiranog alkohola; gdje
The isolated gram-negative bacterial cell according to claim 7, wherein the cell further comprises a polynucleotide sequence encoding a protein of interest. 
Stanica prema zahtjevu 19, naznačena time što stanica sadrži ekspresijsku kasetu ili vektor koji sadrži polinukleotidnu sekvencu koja kodira protein od interesa.
It has been found that industrial byproducts and process dusts are well-suited as correcting agents for adjustment of the raw meal mixture. For production of cement or binder mixtures, the clinker is ground in a manner known per se, either with or without sulfate carriers, to conventional cement finenesses (according to Blaine) of 2000 to 10000 cm2/g, preferably of 3000 to 6000 cm2/g and more preferably of 4000 to 5000 cm2/g. 
Vezivo sukladno barem jednom od zahtjeva 3 do 9, naznačeno time što je ternesit kalcij sulfoaluminat samljeven do stupnja finoće (sukladno Blaineu) opsega od 2000 do 10000 cm?/g, poželjno opsega od 3000 do 6000 cm?/g i poželjnije od 4000 do 5000 cm?/g, sa ili bez sulfatnih nositelja u obliku alkalijskih i/ili zemno alkalijskih sulfata, poželjno u obliku gipsa i/ili hemihidrata i/ili anhidrata i/ili magnezijevog sulfata.
Compound according to any one of the preceding claims for use as a medicament in the treatment of inflammation-associated pain, preferably arthritis, skin inflammation, inflammatory back pain, headache (including neurogenic migraine), inflammatory lesions of the central and peripheral nervous system (neuropathic pain), cancer pain, disorders of the immune system (HIV/AIDS, multiple sclerosis), traumatic pain, postoperative pain, inflamed joints, dental surgery, visceral pain, bone pain, burn injury and/or eye lesions. 
Spoj namijenjen upotrebi kao medikament u skladu s patentnim zahtjevom 7, naznačen time što se bol povezanu s upalom bira iz skupine koju čine artritis, upala kože, upalna bol u leđima, glavobolja, primjerice neurogena migrena, upalne lezije u središnjem i perifernom živčanom sustavu, primjerice neuropatska bol, bol uzrokovana rakom, poremećaji imunosnog sustava, primjerice HIV/AIDS ili multipla skleroza, traumatska bol, postoperativna bol, upaljeni zglobovi, kirurški zahvat na zubalu, visceralna bol, kostobolja, opeklinska ozljeda i lezije oka.
In particular embodiments, the remaining amino acids are then coupled by a N-terminal synthetic strategy. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da su preostale aminokiseline potom povezuju strategijom sinteze N-terminala.
An adhesive composition according to any one of the preceding claims, having the following composition: 
Ljepljiva mješavina u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što ima sljedeći sastav:
A represents a single bond, an oxygen atom, a sulfur atom, NH, or CH2; 
A predstavlja jednostruku vezu, kisikov atom, sumporov atom, NH, ili CH2;
Receptor and Transporter Protein Binding Studies 
Studije vezivanja na proteine receptora i transportera
After adding water to the solution of the active ingredient in the alkoxylated fat a clear solution is obtained. 
Nakon dodavanja vode u otopinu aktivnog sastojka u alkoksiliranoj masti dobiva se bistra otopina.
In another aspect, the crenolanib or a pharmaceutically acceptable salt thereof is administered at least one of continuously, intermittently, systemically, or locally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje najmanje jednom kontinuirano, naizmjenično, sustavno ili lokalno.
At the second technological stage, Meldonium salts are evaporated to dryness if necessary. 
U drugom tchnološkom stupnju, ako je potrebno, mcldonijeve soli se isparc do suhog.
A process for preparing a sterile influenza virus antigen formulation which contains no mercurial preservative, no antibiotic, no formaldehyde and no egg-derived materials, comprising the steps of: (i) growing influenza virus in a cell culture system, in the absence of egg-derived materials and of antibiotics; (ii) inactivating the influenza viruses grown in step (i), in the absence of formaldehyde; and (iii) preparing a vaccine antigen formulation from the inactivated influenza viruses, in the absence of thimerosal. 
Postupak za dobivanje sterilne formulacije antigena virusa influence koja ne sadrži konzervanse sa živom, ne sadrži antibiotik, ne sadrži formaldehid 1 materijale dobivene od jaja, naznačen time da sadrži slijedeće korake: (i) uzgajanje virusa influence u sustavu stanične kulture, bez prisutnosti materijala dobivenih od jaja i antibiotika; (11) inaktiviranje virusa influence uzgojenih u koraku (i), bez prisutnosti formaldehida; te (iii) dobivanja formulacije antigena cjepiva iz inaktiviranih virusa influence, bez prisutnosti timerosala.
The reconstituted and diluted solutions exemplify embodiments of this invention. 
Rekonstruirane i razrijeđene otopine predstavljaju primjere varijanti ovog izuma.
Further subject of the invention is the use of compound of formula (XXII) for the preparation of compound of formula (XXI). 
Primjena spoja formule (XXI) za spravljanje medetomidina, naznačen time da je spoj formule (XXI) definiran kao u zahtjevu 1.
The process according to claim 1, further comprising conducting step a) in a continuously operating mixing apparatus. 
Postupak prema zahtjevu 1, naznačen time da se korak a) provodi u uređaju za neprekidno miješanje.
represents a hydrogen atom, L is selected from -O-, -NH(CO)- and - NH(CO)O- group, and W represents a phenylene group which is substituted with two substituents selected from a chlorine atom, a methoxy group and a cyano group; or 
predstavlja atom vodika, L je odabran iz -O-, -NH(CO)- i -NH(CO)O- grupe, a W predstavlja fenilensku grupu koja je supstituirana s jednim ili dva supstituenta odabrana iz atoma klora, metoksi grupe i cijano grupe ili
The anti-CD40 antibody or antigen-binding fragment or use of any preceding claim, wherein said antibody or antigen-binding fragment thereof binds to human CD40 antigen with an affinity (KD) of at least 10-6 M. 
Antitijelo za uporabu prema bilo kojem od prethodnih Patentnih zahtjeva, naznačeno time, što se spomenuto antitijelo veže za humani CD40 sa afinitetom (Kn) od najmanje oko 10'6 M ili od najmanje oko 10'8M
This allows the piercer to open the container by piercing the sealed outlet automatically when the container unit is forced downwards towards the base part, since the abutment with the base part forces the piercer to move relative to the base unit. 
To omogućuje da bušilo otvori spremnik probijanjem začepljenog izlaza automatski čim se jedinicu spremnika prisili da ide dolje prema osnovnom dijelu, jer dodir s osnovnim dijelom prisiljava bušilo da se pomakne u odnosu na osnovnu jedinicu.
The salt of Claim 1, wherein the crystalline form is Compound 1 sulfate, characterized by a powder X-ray diffraction pattern having at least one peak selected from those at 4.8, 7.7, 8.3, 9.7, 10.2, 12.0, 12.6, 14.5, 15.4, 17.4, 17.9, 18.4, 19.1, 19.5, 21.0, 22.4, 23.3, 23.9, 25.1, and 26.8 degrees 2θ (pattern M), each peak being ± 0.2 degrees 2θ, when measured at about 25°C with Cu Ka radiation at 1.54178 Å . 
Spoj u skladu s patentnim zahtjevom 1, pri čemu je kristalni oblik sulfat Spoja 1, naznačen time, da ga karakterizira rendgenski difraktogram praha koji ima najmanje jedan pik odabran između sljedećih vrijednosti: 4.8, 7.7, 8.3, 9.7, 10.2, 12.0, 12.6, 14.5, 15.4, 17.4, 17.9, 18.4, 19.1, 19.5, 21.0, 22.4, 23.3, 23.9, 25.1 i 26.8 stupnjeva 2θ (uzorak M), pri čemu je svaki vrh ± 0.2 stupnjeva 2θ, izmjereno pri približno 25 °C uz Cu Ka zračenje na 1,54178 θ.
Description of Invention. 
(54) Naziv izuma:
According to the present invention, the term “treatment” encompasses both treatment and prophylaxis of diseases or pathologic conditions. 
Prema ovom izumu, pojam,,liječenje" odnosi sc i na liječenje i na profilaksu bolesti i patoloških stanja.
providing a multi-layer lidding film comprising a seal layer and the seal layer comprises polypropylene (PP) and/or PE. 
Cc) pružanje višeslojnog tankog filma koji sadrži sloj za pričvršćivanje i sloj za pričvršćivanje sadrži polipropilen (PP) i/ili PE.
State of the art 
Stanje tehnike
Both result in improved lozenge composition and appearance. 
Oba ova postupka imaju za rezultat poboljšani sastav i izgled tablete.
Method according to claim 1, characterized in that there are at least three part-flows and the said emission flow is at essentially the maximum point of the velocity distribution of the gas flow. 
Postupak sukladno zahtjevu 1, naznačen time, da ima najmanje tri djelomična tijeka, a navedeni tijek emisije (a) nalazi se na maksimalnoj brzmi protoka plina.
reacting a compound of formula (i) wherein X, R1, R2, R3, R4 are as defined in claim 1; 
reakciju spoja formule (i): gdje R2 i R3 su kao što su definirani u patentnom zahtjevu 1;
The process of claim 1, wherein at least a portion of the process occurs in equipment comprising a reaction zone, a separation zone, and a condensing zone. The process of claim 5, wherein the separation zone comprises a distillation component. 
Postupak prema zahtjevu 1, gdje se barem dio postupka pripreme 1,1,1,2,3-pentakloropropana odvija u opremi koja obuhvaća reakcijsku zonu, zonu odvajanja koja po izboru ima destilacijsku komponentu, i zonu kondenzacije.
Compound XX can be derived from compound XVI by copper or palladium catalysed reaction with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (or related boronic acid derivatives) as described by Eastwood Tetrahedron Lett. 
Spoj XX može biti deriviran iz spoja XVI reakcijom uz bakreni ili paladijev katalizator s 4-(4,4,5,5-tetrametil-[1,3,2 |dioksaborolan-2-il)-3,6-dihidro-2H-piridin-1-karboksilna kiselina tert-butil esterom (ili odnosnim derivatima boronske kiseline) prema opisu u Eastwood Tetrahedron Lett.
The method of any of the preceding claims, wherein for the GoP-structure estimation of subsequent GoPs either new arrays of frame sizes are captured for each of the subsequent GoPs, or average of the elements of current and previous arrays of frame sizes are being used. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se za procjenjivanje strukture GoP-a za uzastopne GoP-ove bilo digitalizira nove matrice veličina kadrova za svaki od uzastopnih GoP-ova, ili se upotrebljava prosječna vrijednost elemenata trenutne i prethodnih matrica veličina kadrova.
Preparation of the Compound of the Invention 
PRIPREMA SPOJA IZ OVOGA IZUMA
R3 is hydrogen, halogen, acyl, carbamoyl, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted lower alkynyl or amino; 
R* je vodik, halogen, acil, karbamoil, supstituirani ili nesupstituirani niži alkil, supstituirani ili nesupstituirani alkenil, supstituirani ili nesupstituirani niži alkinil ili amino; i
The composition for use of claim 1, wherein the polypeptide does not include amino acid residues 1-45 of SEQ ID NO: 3. 
Polipeptid prema patentnom zahtjevu 8, naznačen time što dvolančani polipeptid sadrži aminokiselinsku sekvencu koja ima najmanje 90% homologije sa SEQ ID NO:13.
Reading of the plate falls in three phases: 
Datum objave europske prijave patenta:
The present invention provides a heterocyclic compound or a salt thereof represented by General Formula (1): 
Heterociklički spoj ili njegova sol, naznačen time, da je predstavljen općom formulom (1): o T E
Benzoic acid or a benzoic acid salt for use in a method of mitigating one or more symptoms of a neuropsychiatric disorder, wherein the benzoic acid salt is selected from the group consisting of sodium benzoate, potassium benzoate, calcium benzoate, and lithium benzoate, wherein the amount of the benzoic acid or benzoic acid salt is sufficient to mitigate one or more of said symptoms and ranges from about 5 mg to about 500 g; and the neuropsychiatric disorder is depression, attention deficit hyperactivity disorder, loss in cognition and/or neurodegeneration, bipolar, anxiety, post-traumatic stress disorder, panic disorder, or obsessive-compulsive disorder. 
Benzojeva kiselina ili sol benzojeve kiseline za uporabu u metodi ublažavanja jednog ili više simptoma shizofrenije pri čemu se sol benzojeve kiseline bira iz skupine koja se sastoji od natrijevog benzoata, kalijevog benzoata, kalcijevog benzoata i litijevog benzoata i pri čemu je količina benzojeve kiseline ili soli benzojeve kiseline dovoljna za ublažavanje jednog ili više spomenutih simptoma i varira od približno 5 mg do približno 500g.
The medicament for use according to claim 1, or glatiramer acetate for use according to claim 2, wherein frequency of immediate post injection reaction or of injection site reaction relative to frequency experienced with daily subcutaneous administration of 20mg glatiramer acetate is reduced. 
Lijek za uporabu prema patentnom zahtjevu 1 ili glatiramer acetat za uporabu prema patentnom zahtjevu 2, naznačeni time, da je učestalost reakcije neposredno nakon injekcije ili reakcije na mjestu uboda smanjena u odnosu na učestalost pretrpljenu uz dnevno supkutano davanje od 20 mg glatiramer acetata.
The rodent of claim 1, wherein the nucleotide sequence encoding a chimeric human/rodent MHC II a polypeptide is expressed under regulatory control of endogenous rodent MHC II a promoter and regulatory elements and/or the nucleotide sequence encoding a chimeric human/rodent MHC II B polypeptide is expressed under regulatory control of endogenous rodent MHC II B promoter and regulatory elements. 
na endogenom MHC II-a-gen-lokusu, zamjenu nukleotidne sekvence koja kodira glodarski MHC II-a-polipeptid s prvom nukleotidnom sekvencom koja kodira kimerni ljudski/glodarski MHC II-a-polipeptid i/ili na endogenom MHC II-B-gen-lokusu, zamjenu nukleotidne sekvence koja kodira glodarski MHC II-B-polipeptid s drugom nukleotidnom sekvencom koja kodira kimerni ljudski/glodarski MHC II-B-polipeptid.
providing said first metal plate (1), acoustic insulation layer (3) and second metal plate (2), wherein the second metal plate has been or is provided with openings, hereinafter referred to as welding openings (4), at locations where the locally welded joints will be realized; 
osiguravanju navedene prve metalne ploče (1), sloja zvučne izolacije (3) 1 druge metalne ploče (2), gdje druga metalna ploča ima ili su na njoj načinjeni otvori, koje se nadalje navodi kao otvore za zavarivanje (4), na mjestima gdje će se načiniti lokalno zavarene spojeve;
Another instance describes a compound of formula (I-L) selected from: 
Spoj sukladno patentnom zahtjevu 5, formule (I-L): ž a
Dissolution is visually checked before continuing, and dissolution is considered complete when it is so appreciated visually The pH of the solution is checked and adjusted to a value in the range from about 1 to about 5, more preferably in the range from about 2 to about 4.5, even more preferably in the range from about 3 to about 4.5, and most preferably to a pH of about 4.0 by slow addition of a suitable acid. 
Otapanje je vizualno provjereno prije nastavka, i otapanje je uzeto kao završeno kada je to vizualno tako procijenjeno. pH vrijednost otopine provjerena je i podešena do vrijednosti u opsegu od oko 1 do oko 5, poželjnije u opsegu od oko 2 do oko 4 5, čak poželjnije u opsegu od oko 3 do oko 4.5, a najpoželjnije do pH vrijednosti od oko 4.0 laganim dodavanjem pogodne kiseline.
o a processing unit (2,2') adapted to control said branches, to adjust the value of said direct current component of the reference current until the root-mean-square value of the sinusoidal component reach a maximum value, o said processing unit calculates the value of the direct current to be measured as the value of the reference direct current component sent to the secondary winding of said transformer multiplied by a proportionality constant obtained during adjusting the value of said direct current. 
◦ jednu granu za generiranje referentne struje, koja se sastoji od sinusoidalne struje s unaprijed određenom efektivnom vrijednosti i od istosmjerne struje koja se može podešavati, i koju referentnu struju se treba dovesti u sekundarni namot (42, 42 ́) navedenog transformatora, ◦ jednu granu za detektiranje sinusoidalne komponente navedene referentne struje sekundarnog namota navedenog transformatora, ◦ jedinicu za obradu podataka (2, 2 ́) koja je prilagođena da upravlja navedenim granama i da namješta vrijednost komponente istosmjerne referentne struje, sve dok efektivna vrijednost sinusoidalne komponente ne dostigne maksimalnu vrijednost, ◦ pri čemu navedena jedinica za obradu podataka izračunava vrijednost istosmjerne struje koju treba izmjeriti kao vrijednost komponente referentne istosmjerne struje koja je uvedena u sekundarni namot navedenog transformatora pomnoženu s konstantom proporcionalnosti, koja se dobiva za vrijeme namještanja vrijednosti navedene istosmjerne struje.
seeding the solution with crystalline form 11 of N -benzoyi-staurosporine; 
(b) kultiviranje otopine s kristalnim oblikom II od N-benzoil-staurosporina;
"acyloxy", as used herein, pertains to a -OC(=O)R group, wherein R is a C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group; 
"aciloksi", kako se ovdje koristi, odnosi se na -OC(=0)R skupinu, pri čemu R je C,; alkilna skupina, C329 heterociklilna skupina, ili C5. arilna skupina;